Treatment options for migraine have expanded rapidly over the past few years. The latest success in a phase II trial of a new class of drugs for migraine holds the promise of another alternative, with important implications for our understanding of migraine and its clinical management.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Ashina, M., Phul, R., Khodaie, M., Löf, E. & Florea, I. A monoclonal antibody to PACAP for migraine prevention. N. Engl. J. Med. 391, 800–809 (2024).
Mitsikostas, D. D. et al. The 5-HT1F receptor as the target of ditans in migraine — from bench to bedside. Nat. Rev. Neurol. 19, 489–505 (2023).
Edvinsson, L., Haanes, K. A., Warfvinge, K. & Krause, D. N. CGRP as the target of new migraine therapies — successful translation from bench to clinic. Nat. Rev. Neurol. 14, 338–350 (2018).
Ashina, H. et al. Pituitary adenylate cyclase-activating polypeptide signalling as a therapeutic target in migraine. Nat. Rev. Neurol. https://doi.org/10.1038/s41582-024-01011-4 (2024).
Schytz, H. W. et al. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 132, 16–25 (2009).
Ashina, M. et al. A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention. Cephalalgia 41, 33–44 (2021).
Rasmussen, N. B. et al. The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled study. J. Headache Pain 24, 60 (2023).
Vollesen, A. L. H. et al. The effect of pituitary adenylate cyclase-activating peptide-38 and vasoactive intestinal peptide in cluster headache. Cephalalgia 40, 1474–1488 (2020).
Al-Khazali, H. M. et al. Hypersensitivity to PACAP-38 in post-traumatic headache: a randomized clinical trial. Brain 147, 1312–1320 (2024).
Igarashi, H. et al. Underrecognition of migraine-related stigmatizing attitudes and social burden: results of the OVERCOME Japan study. Brain Behav. 14, e3547 (2024).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Mitsikostas, D.D., Rapoport, A. Continuing evolution of migraine-specific therapies — targeting migraine with precision and persistence. Nat Rev Neurol 20, 645–646 (2024). https://doi.org/10.1038/s41582-024-01026-x
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41582-024-01026-x
